MICHAEL S KAY portrait
  • Professor, Biochemistry Research
801-585-5021

Research Keywords

  • Virology
  • Protein Design
  • Drug Design
  • Peptides
  • Protein Chemistry
  • Chemical Biology

Presentations

  • University of Utah, School of Medicine Series. , , 2012.
  • Navigen Pharmaceuticals. , , 2011.
  • Brigham Young University. , , 2011.
  • Los Alamos National Lab. , , 2010.
  • Caltech. , , 2010.
  • U. of Toronto. , , 2010.
  • Tibotec (Belgium). , , 2009.
  • Weizmann Institute. , , 2009.
  • MIT. , , 2008.
  • UNC Chapel Hill. , , 2008.
  • New England Primate Research Center. , , 2008.
  • U. Massachusetts Medical School. , , 2008.
  • SUNY Upstate. , , 2007.
  • Tibotec (Belgium). , , 2006.
  • Merck Research Labs. , , 2005.
  • Weizmann Institute. , , 2004.
  • Merck Research Labs. , , 2002.
  • Locus Pharmaceuricals. , , 2002.
  • Thomas Jefferson University. , , 2002.
  • University of Utah. , , 2001.
  • University of California, Davis. , , 1997.
  • NIH Meeting on the Structure of AIDS-Related Systems. , , 2011.
  • Roche Colorado Peptide Symposium. , , 2011.
  • Lorne Conference of Protein Structure and Function (Australia). , , 2010.
  • Alliance for Microbicide Development. , , 2009.
  • Protein Society. , , 2009.
  • International HIV Drug Resistance Workshop (Sitges, Spain). , , 2008.
  • Proteins Gordon Research Conference. , , 2007.
  • Cell Biology of Virus Entry, Replication and Pathogenesis Keystone Meeting. , , 2006.
  • NIH Meeting on the Structure of AIDS-Related Systems. , , 2005.
  • West Coast Retrovirus Meeting. , , 2005.

Languages

  • English, Fluent.

Publications

  • Mesquita PM, Srinivasan P, Johnson TJ, Rastogi R, Evans-Strickfaden T, Kay MS, Buckheit KW, Buckheit RW Jr, Smith JM, Kiser PF, Herold BC (date unknown). Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties. Vol. 10, 113. Accepted, .
  • Weinstock MT, Jacobsen MT, Kay MS (date unknown). Synthesis and folding of a mirror-image enzyme reveals ambidextrous chaperone activity. Vol. 111, 11679-84. Accepted, .
  • Denton PW, Othieno F, Martinez-Torres F, Zou W, Krisko JF, Fleming E, Zein S, Powell DA, Wahl A, Kwak YT, Welch BD, Kay MS, Payne DA, Gallay P, Appella E, Estes JD, Lu M, Garcia JV (date unknown). One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates. Vol. 85, 7582-93. Accepted, .
  • Francis JN, Redman JS, Eckert DM, Kay MS (date unknown). Design of a modular tetrameric scaffold for the synthesis of membrane-localized D-peptide inhibitors of HIV-1 entry. Vol. 23, 1252-8. Accepted, .
  • Clinton TR, Weinstock MT, Jacobsen MT, Szabo-Fresnais N, Pandya MJ, Whitby FG, Herbert AS, Prugar LI, McKinnon R, Hill CP, Welch BD, Dye JM, Eckert DM, Kay MS (date unknown). Design and characterization of ebolavirus GP prehairpin intermediate mimics as drug targets. Vol. 24, 446-63. Accepted, .
  • Pang HB, Hevroni L, Kol N, Eckert DM, Tsvitov M, Kay MS, Rousso I (date unknown). Virion stiffness regulates immature HIV-1 entry. Vol. 10, 4. Accepted, .